+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Spine Biologics - Global Strategic Business Report

  • PDF Icon

    Report

  • 196 Pages
  • December 2024
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 5140127
The global market for Spine Biologics was estimated at US$2.1 Billion in 2023 and is projected to reach US$2.9 Billion by 2030, growing at a CAGR of 4.4% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Why Are Spine Biologics Transforming Spine Surgery and Recovery?

Spine biologics are transforming spine surgery and recovery by offering innovative solutions for bone regeneration, fusion enhancement, and tissue repair. These biologics, which include bone grafts, growth factors, stem cells, and synthetic biomaterials, are widely used in spinal fusion procedures, disc replacement, and spinal deformity correction. With the increasing prevalence of spinal disorders such as degenerative disc disease, scoliosis, and trauma-related injuries, the demand for biologics that improve fusion rates, reduce healing times, and minimize complications is growing rapidly. Spine biologics are particularly advantageous in minimally invasive spine surgery (MISS) and complex spinal reconstructions, providing better clinical outcomes and faster recovery for patients.

How Are Technological Advancements Impacting the Spine Biologics Market?

Technological advancements in biomaterials, synthetic bone grafts, and cell-based therapies are significantly enhancing the effectiveness, safety, and application scope of spine biologics. The development of next-generation biologics, such as demineralized bone matrices (DBMs), recombinant human growth factors, and allograft bone products, is providing more effective options for spinal fusion and bone healing. Innovations in stem cell-based therapies, gene therapy, and regenerative medicine are gaining traction, offering new possibilities for tissue repair, nerve regeneration, and personalized spine care. Additionally, the emergence of combination biologics and hybrid solutions, which integrate multiple biologic agents and synthetic materials, is expanding the treatment options available for spine surgeons, supporting the growth of the spine biologics market.

Which Market Segments Are Leading the Growth of the Spine Biologics Industry?

Product types include bone grafts, bone graft substitutes, platelet-rich plasma (PRP), bone morphogenetic proteins (BMPs), and cell-based matrices, with bone graft substitutes holding the largest market share due to their widespread use in spinal fusion procedures. Applications of spine biologics span spinal fusion, disc replacement, trauma repair, and deformity correction, with spinal fusion being the dominant segment due to the high demand for biologics that enhance fusion rates and promote bone healing. End-use sectors include hospitals, specialized clinics, and research institutes, with hospitals leading the market due to their advanced surgical capabilities and multidisciplinary care teams. Geographically, North America and Europe are the largest markets for spine biologics, driven by high adoption of regenerative medicine and advanced biologic products, while Asia-Pacific is expected to witness rapid growth due to rising healthcare investments and increasing prevalence of spinal disorders.

What Are the Key Drivers of Growth in the Spine Biologics Market?

The growth in the spine biologics market is driven by several factors, including rising demand for biologics in minimally invasive spine surgery (MISS), technological advancements in biomaterials, synthetic bone grafts, and regenerative medicine, and the increasing focus on enhancing fusion rates, bone regeneration, and healing times. The need to provide effective, safe, and personalized biologics for a wide range of spinal conditions is driving the demand for spine biologics across various surgical and non-surgical settings. Technological innovations in next-generation biologics, stem cell-based therapies, gene therapy, and combination biologics, coupled with advancements in regenerative medicine, synthetic biomaterials, and personalized spine care, are enhancing the efficacy, safety, and marketability of spine biologics, supporting market growth. The expansion of biologic applications in trauma, degenerative disc disease, scoliosis treatment, and spinal deformity correction, along with the growing emphasis on evidence-based practice, clinical guidelines, and patient education, is creating new opportunities for market players. Additionally, the focus on developing cost-effective, scalable, and hybrid spine biologics for diverse patient populations is further propelling the growth of the spine biologics market.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Spinal Allografts segment, which is expected to reach US$1.4 Billion by 2030 with a CAGR of a 3.9%. The Bone Graft Substitutes segment is also set to grow at 5.0% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, which was valued at $572.7 Million in 2023, and China, forecasted to grow at an impressive 6.8% CAGR to reach $593.8 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Spine Biologics Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Spine Biologics Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Spine Biologics Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of major players such as AlloSource, Alphatec Spine, Inc., DePuy Synthes, and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Select Competitors (Total 46 Featured):

  • AlloSource
  • Alphatec Spine, Inc.
  • DePuy Synthes
  • Exactech, Inc.
  • Globus Medical, Inc.
  • Harvest Technologies
  • Medtronic, Inc.
  • NuVasive, Inc.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Global Economic Update
  • Spine Biologics - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Rising Demand for Biologics in Minimally Invasive Spine Surgery (MISS) Drives Spine Biologics Market Growth
  • Increasing Focus on Enhancing Fusion Rates, Bone Regeneration, and Healing Times Spurs Adoption of Spine Biologics
  • Technological Advancements in Biomaterials, Synthetic Bone Grafts, and Cell-Based Therapies Propel Market Innovation
  • Growing Emphasis on Reducing Post-Operative Complications and Repeat Surgeries Expands Addressable Market Opportunity
  • Emergence of Next-Generation Biologics, Growth Factors, and Stem Cell-Based Products Strengthens Business Case
  • Rising Adoption of Biologics in Lumbar, Cervical, and Thoracic Spine Procedures Accelerates Market Demand
  • Focus on Developing Combination Biologics and Hybrid Solutions for Enhanced Therapeutic Efficacy Drives Market Competitiveness
  • Growing Application of Spine Biologics in Trauma, Degenerative Disc Disease, and Scoliosis Treatment Fuels Market Expansion
  • Expansion of Biologic Applications in Spinal Fusion, Disc Replacement, and Spinal Deformity Correction Spurs Market Potential
  • Shift Towards Regenerative Medicine, Personalized Spine Care, and Patient-Specific Biologics Expands Market Opportunities
  • Increasing Emphasis on Patient Education, Surgical Guidelines, and Evidence-Based Practice Creates New Opportunities
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Spine Biologics Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
  • Table 2: World Recent Past, Current & Future Analysis for Spine Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 3: World Historic Review for Spine Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 4: World 16-Year Perspective for Spine Biologics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
  • Table 5: World Recent Past, Current & Future Analysis for Spinal Allografts by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 6: World Historic Review for Spinal Allografts by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 7: World 16-Year Perspective for Spinal Allografts by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 8: World Recent Past, Current & Future Analysis for Bone Graft Substitutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 9: World Historic Review for Bone Graft Substitutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 10: World 16-Year Perspective for Bone Graft Substitutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 11: World Recent Past, Current & Future Analysis for Cell-based Matrix by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 12: World Historic Review for Cell-based Matrix by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 13: World 16-Year Perspective for Cell-based Matrix by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 14: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 15: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 16: World 16-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 17: World Recent Past, Current & Future Analysis for Ambulatory Surgery Centers (ASCs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 18: World Historic Review for Ambulatory Surgery Centers (ASCs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 19: World 16-Year Perspective for Ambulatory Surgery Centers (ASCs) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 20: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 21: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 22: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
III. MARKET ANALYSIS
UNITED STATES
  • Spine Biologics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • Table 23: USA Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 24: USA Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 25: USA 16-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2014, 2024 & 2030
  • Table 26: USA Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 27: USA Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 28: USA 16-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2014, 2024 & 2030
CANADA
  • Table 29: Canada Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 30: Canada Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 31: Canada 16-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2014, 2024 & 2030
  • Table 32: Canada Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 33: Canada Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 34: Canada 16-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2014, 2024 & 2030
JAPAN
  • Spine Biologics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • Table 35: Japan Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 36: Japan Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 37: Japan 16-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2014, 2024 & 2030
  • Table 38: Japan Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 39: Japan Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 40: Japan 16-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2014, 2024 & 2030
CHINA
  • Spine Biologics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • Table 41: China Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 42: China Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 43: China 16-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2014, 2024 & 2030
  • Table 44: China Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 45: China Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 46: China 16-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2014, 2024 & 2030
EUROPE
  • Spine Biologics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • Table 47: Europe Recent Past, Current & Future Analysis for Spine Biologics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 48: Europe Historic Review for Spine Biologics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 49: Europe 16-Year Perspective for Spine Biologics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
  • Table 50: Europe Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 51: Europe Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 52: Europe 16-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2014, 2024 & 2030
  • Table 53: Europe Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 54: Europe Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 55: Europe 16-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2014, 2024 & 2030
FRANCE
  • Spine Biologics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • Table 56: France Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 57: France Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 58: France 16-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2014, 2024 & 2030
  • Table 59: France Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 60: France Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 61: France 16-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2014, 2024 & 2030
GERMANY
  • Spine Biologics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • Table 62: Germany Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 63: Germany Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 64: Germany 16-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2014, 2024 & 2030
  • Table 65: Germany Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 66: Germany Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 67: Germany 16-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2014, 2024 & 2030
ITALY
  • Table 68: Italy Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 69: Italy Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 70: Italy 16-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2014, 2024 & 2030
  • Table 71: Italy Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 72: Italy Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 73: Italy 16-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2014, 2024 & 2030
UNITED KINGDOM
  • Spine Biologics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • Table 74: UK Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 75: UK Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 76: UK 16-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2014, 2024 & 2030
  • Table 77: UK Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 78: UK Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 79: UK 16-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2014, 2024 & 2030
SPAIN
  • Table 80: Spain Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 81: Spain Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 82: Spain 16-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2014, 2024 & 2030
  • Table 83: Spain Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 84: Spain Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 85: Spain 16-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2014, 2024 & 2030
RUSSIA
  • Table 86: Russia Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 87: Russia Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 88: Russia 16-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2014, 2024 & 2030
  • Table 89: Russia Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 90: Russia Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 91: Russia 16-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2014, 2024 & 2030
REST OF EUROPE
  • Table 92: Rest of Europe Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 93: Rest of Europe Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 94: Rest of Europe 16-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2014, 2024 & 2030
  • Table 95: Rest of Europe Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 96: Rest of Europe Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 97: Rest of Europe 16-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2014, 2024 & 2030
ASIA-PACIFIC
  • Spine Biologics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • Table 98: Asia-Pacific Recent Past, Current & Future Analysis for Spine Biologics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 99: Asia-Pacific Historic Review for Spine Biologics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 100: Asia-Pacific 16-Year Perspective for Spine Biologics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
  • Table 101: Asia-Pacific Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 102: Asia-Pacific Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 103: Asia-Pacific 16-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2014, 2024 & 2030
  • Table 104: Asia-Pacific Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 105: Asia-Pacific Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 106: Asia-Pacific 16-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2014, 2024 & 2030
AUSTRALIA
  • Spine Biologics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
INDIA
  • Spine Biologics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
SOUTH KOREAREST OF ASIA-PACIFIC
LATIN AMERICA
  • Spine Biologics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
ARGENTINABRAZILMEXICOREST OF LATIN AMERICA
MIDDLE EAST
  • Spine Biologics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
IRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EAST
AFRICA
  • Spine Biologics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
IV. COMPETITION

Companies Mentioned

  • AlloSource
  • Alphatec Spine, Inc.
  • DePuy Synthes
  • Exactech, Inc.
  • Globus Medical, Inc.
  • Harvest Technologies
  • Medtronic, Inc.
  • NuVasive, Inc.

Table Information